89 related articles for article (PubMed ID: 22413822)
1. Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers.
Jansen TL; Mulder CJ
Expert Opin Biol Ther; 2012 Apr; 12(4):391-3. PubMed ID: 22413822
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
3. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
Cansu DU; Kalifoglu T; Korkmaz C
J Rheumatol; 2008 Mar; 35(3):421-4. PubMed ID: 18203328
[TBL] [Abstract][Full Text] [Related]
4. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
[TBL] [Abstract][Full Text] [Related]
8. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
9. Chronic viral hepatitis and TNF-alpha blockade.
Raftery G; Griffiths B; Kay L; Kane D
Rheumatology (Oxford); 2007 Aug; 46(8):1381; author reply 1381-2. PubMed ID: 17567635
[No Abstract] [Full Text] [Related]
10. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers?
Jansen TL
Arthritis Res Ther; 2010; 12(1):103. PubMed ID: 20156318
[TBL] [Abstract][Full Text] [Related]
11. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
12. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
13. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
Caporali R; Bobbio-Pallavicini F; Atzeni F; Sakellariou G; Caprioli M; Montecucco C; Sarzi-Puttini P
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):749-54. PubMed ID: 20535784
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
15. TNF inhibitors in the treatment of arthritis.
Lorenz HM
Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
[TBL] [Abstract][Full Text] [Related]
16. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
17. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab.
Anelli MG; Torres DD; Manno C; Scioscia C; Iannone F; Covelli M; Schena FP; Lapadula G
Arthritis Rheum; 2005 Aug; 52(8):2519-20. PubMed ID: 16052569
[No Abstract] [Full Text] [Related]
18. [Treatment strategy for rheumatoid arthritis in Croatia].
Curković B
Reumatizam; 2008; 55(2):39-44. PubMed ID: 19024273
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
20. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
Liang GC; Cordero M; Dyer A; Chang RW
J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]